Tectonic Therapeutic Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-13.3%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$5.32next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| TX45 APEX Phase 2 Topline Data Release | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly236.9MTarget: Sufficient to fund operations into Q4 2028
TX45 APEX Phase 2 Trial Enrollment Quarterly191.0Target: 191 (100% Enrolled)
TX2100 Phase 1a Cohorts Dosed Quarterly4.0Target: Complete ascending-dose cohorts
Watch Items
- TX45 APEX Phase 2 Topline Data in PH-HFpEFTrigger: Topline results releaseAction: Evaluate safety and change from baseline in pulmonary vascular resistance (PVR) to determine progression to Phase 3
- TX2100 Phase 1a Topline Data in Healthy VolunteersTrigger: Topline results releaseAction: Assess safety, tolerability, and pharmacokinetics to support initiation of Phase 2 proof-of-concept trial in early 2027
- TX45 ALPINE Phase 2 Trial Progress in PH-ILDTrigger: Enrollment milestones and site activationsAction: Monitor patient screening and enrollment rates to project data readout timeline
Research as of 19 Jun 2026